Incidence of Different Types of Cancer in the Follow-up Period After Primary Diagnosis and Treatment of Melanoma. Single-centre 4-year Follow-up on a Population of 709 Patients

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2023 Aug 7

PMID 37545825

Authors

Marcin Zietek

Jedrzej Wierzbicki

Maciej Nowacki

Rafal Czajkowski

Piotr Wronski

Katarzyna Nowacka

Edyta Pawlak

Adam Maciejczyk

Rafal Matkowski

Affiliations

Soon will be listed here.

Abstract

Introduction: Follow-up plays a key role in melanoma management, especially in the first years after diagnosis. During this period it is crucial to assess possible recurrence, progression of the disease or treatment complications. An important aspect is also the possibility of formation of new primary foci or other skin cancers.

Aim: To assess the coincidence of skin lesions and cancers among the melanoma patients.

Material And Methods: Patients treated in the Comprehensive Cancer Centre between 2019 and 2022 were retrospectively analysed for occurrence of skin lesions diagnosed during the follow-up, and confirmed by biopsy. The lesions considered included skin cancers, dysplastic nevus and actinic keratosis.

Results: In 100 (14%) out of 709 enrolled patients, 184 lesions were diagnosed. In 7 patients it was melanoma, in 49 BCC, and in 16 SCC. Dysplastic nevus and actinic keratosis were excised in 28 and 14 patients, respectively. More than one site of the skin lesion was observed in 39 patients, and more than one type of the lesion in 13 patients. Patients with lesions were on average 8.6 years older ( < 0.001), had less advanced tumours ( = 0.010), and primary melanoma was more often located on the head and neck ( = 0.056).

Conclusions: Among melanoma patients, particular attention must be paid to, apart from early detection of melanoma recurrence and progression, the occurrence of new primary foci or independent skin cancers.

References

Trotter S, Sroa N, Winkelmann R, Olencki T, Bechtel M . A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013; 6(9):18-26. PMC: 3780800. View

Modrakowska P, Balik K, Maj M, Bajek A . Novel therapies for advanced skin carcinomas. Postepy Dermatol Alergol. 2020; 37(5):660-670. PMC: 7675086. DOI: 10.5114/ada.2020.100479. View

Frank C, Sundquist J, Hemminki A, Hemminki K . Risk of other Cancers in Families with Melanoma: Novel Familial Links. Sci Rep. 2017; 7:42601. PMC: 5309808. DOI: 10.1038/srep42601. View

Leiter U, Garbe C . Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. Adv Exp Med Biol. 2008; 624:89-103. DOI: 10.1007/978-0-387-77574-6_8. View

Carlos G, Anforth R, Clements A, Menzies A, Carlino M, Chou S . Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatol. 2015; 151(10):1103-9. DOI: 10.1001/jamadermatol.2015.1745. View

Dalal K, Zhou Q, Panageas K, Brady M, Jaques D, Coit D . Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol. 2008; 15(8):2206-14. DOI: 10.1245/s10434-008-9985-z. View

Watts C, Dieng M, Morton R, Mann G, Menzies S, Cust A . Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol. 2014; 172(1):33-47. DOI: 10.1111/bjd.13403. View

Bradford P, Freedman D, Goldstein A, Tucker M . Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010; 146(3):265-72. PMC: 3076705. DOI: 10.1001/archdermatol.2010.2. View

Gill A, Gosain R, Bhandari S, Gosain R, Gill G, Abraham J . "Lost to Follow-up" Among Adult Cancer Survivors. Am J Clin Oncol. 2017; 41(10):1024-1027. DOI: 10.1097/COC.0000000000000408. View

10.

Leiter U, Buettner P, Eigentler T, Brocker E, Voit C, Gollnick H . Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2011; 66(1):37-45. DOI: 10.1016/j.jaad.2010.09.772. View

11.

Maubec E, Chaudru V, Mohamdi H, Grange F, Patard J, Dalle S . Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer. 2011; 116(24):5716-24. DOI: 10.1002/cncr.25562. View

12.

Lipitz-Snyderman A, Pfister D, Classen D, Atoria C, Killen A, Epstein A . Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer. 2017; 123(23):4728-4736. PMC: 7539686. DOI: 10.1002/cncr.30916. View

13.

Fraga-Braghiroli N, Grant-Kels J, Oliviero M, Rabinovitz H, Ferenczi K, Scope A . The role of reflectance confocal microscopy in differentiating melanoma in situ from dysplastic nevi with severe atypia: A cross-sectional study. J Am Acad Dermatol. 2020; 83(4):1035-1043. DOI: 10.1016/j.jaad.2020.05.071. View

14.

Jacobs L, Shulman L . Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017; 18(1):e19-e29. DOI: 10.1016/S1470-2045(16)30386-2. View

15.

Emery J, Shaw K, Williams B, Mazza D, Fallon-Ferguson J, Varlow M . The role of primary care in early detection and follow-up of cancer. Nat Rev Clin Oncol. 2013; 11(1):38-48. DOI: 10.1038/nrclinonc.2013.212. View

16.

Finet A, Amini-Adle M, Balme B, Colson F, Thomas L . Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?. Clin Rheumatol. 2012; 32(2):277-80. DOI: 10.1007/s10067-012-2114-1. View

17.

Goldstein A, Tucker M . Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):528-32. PMC: 3616416. DOI: 10.1158/1055-9965.EPI-12-1346. View

18.

L Hoeg B, Bidstrup P, Karlsen R, Friberg A, Albieri V, Dalton S . Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev. 2019; 2019(11). PMC: 6870787. DOI: 10.1002/14651858.CD012425.pub2. View

19.

Zietek M, Zdzienicki M, Wierzbicki J, Cybulska-Stopa B, Krotewicz M, Lobaziewicz W . Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies. Postepy Dermatol Alergol. 2023; 39(6):1141-1150. PMC: 9837581. DOI: 10.5114/ada.2022.119971. View